chr2-47799588-CAGTA-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.1610_1613delAGTA(p.Lys537IlefsTer33) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251346Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135848
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:2
This variant deletes 4 nucleotides in exon 4 of the MSH6 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with Lynch syndrome (PMID: 33647816), or Lynch syndrome-associated cancers (PMID: 28975465, 29360161). This variant has been identified in 1/251346 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Variant summary: The MSH6 c.1610_1613delAGTA (p.Lys537Ilefs) variant results in a premature termination codon, predicted to cause a truncated or absent MSH6 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.1634_1637delAAGA, c.1637_1638delAG). One in silico tool predicts a damaging outcome for this variant. This variant was found in 1/121328 control chromosomes at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic MSH6 variant (0.0001421). The variant was reported in a conference abstract (European Human Genetics Conference 2014) in a patient with multiple primary tumors between 21 and 27 years of age including two metachronous colorectal cancers, a fillodes tumour of the breast, a glioblastoma and a clear cell carcinoma of the ovaries who also carried MSH6 p.Arg1076His (not classified by LabCorp, VUS in ClinVar). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as likely pathogenic. -
not provided Pathogenic:2
- -
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Observed in patients with Lynch-related cancers and tumor studies consistent with pathogenic variants in this gene (Siraj et al. 2017, Dudley et al. 2018); This variant is associated with the following publications: (PMID: 31350202, 28975465, 29360161, 28152038, 29625052, 30787465) -
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Lys537Ilefs*33) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with colorectal and pancreatic cancer (PMID: 28514183, 28975465, 29360161). ClinVar contains an entry for this variant (Variation ID: 216859). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1610_1613delAGTA pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a deletion of 4 nucleotides at nucleotide positions 1610 to 1613, causing a translational frameshift with a predicted alternate stop codon (p.K537Ifs*33). This mutation was identified in a Saudi individual with colorectal cancer (Siraj AK et al. Hum. Genet. 2017 11;136:1431-1444) and in a woman with both pancreatic and rectal cancer (Dudley B et al. Cancer 2018 Apr;124:1691-1700). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Endometrial carcinoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at